Bahl & Gaynor Inc. Lowers Stock Holdings in Amgen Inc. $AMGN

Bahl & Gaynor Inc. reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 31.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 198,402 shares of the medical research company’s stock after selling 90,516 shares during the quarter. Bahl & Gaynor Inc.’s holdings in Amgen were worth $55,989,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. New Age Alpha Advisors LLC increased its holdings in shares of Amgen by 3.0% during the third quarter. New Age Alpha Advisors LLC now owns 41,651 shares of the medical research company’s stock valued at $11,754,000 after acquiring an additional 1,211 shares in the last quarter. Holderness Investments Co. grew its position in Amgen by 2.2% during the 3rd quarter. Holderness Investments Co. now owns 7,786 shares of the medical research company’s stock valued at $2,197,000 after purchasing an additional 169 shares during the last quarter. Patrick M Sweeney & Associates Inc. grew its position in Amgen by 6.4% during the 3rd quarter. Patrick M Sweeney & Associates Inc. now owns 1,037 shares of the medical research company’s stock valued at $293,000 after purchasing an additional 62 shares during the last quarter. Strategies Wealth Advisors LLC bought a new stake in Amgen during the 3rd quarter valued at about $278,000. Finally, 49 Wealth Management LLC raised its holdings in Amgen by 4.6% in the third quarter. 49 Wealth Management LLC now owns 1,151 shares of the medical research company’s stock worth $325,000 after buying an additional 51 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported a new evolocumab bioavailability study that refines dosing/PK assessment for its PCSK9 cholesterol franchise, signaling management’s continued investment in a long‑lived cardiovascular product line and potential lifecycle optimization. Amgen Fine-Tunes Evolocumab
• Positive Sentiment: Amgen advanced maridebart (cafraglutide) toward a Phase 2b obesity and liver‑fat trial — news that expands the company’s obesity pipeline and supports upside potential beyond core biologics. Pipeline progress tends to lift pharma multiples. Amgen Advances Maridebart
• Positive Sentiment: Coverage and momentum narratives are supportive — Zacks highlights AMGN as a top long‑term momentum stock, which can attract trend‑driven and fund flows. Why Amgen is a Top Momentum Stock
• Positive Sentiment: Market headlines note AMGN reaching an all‑time high and outperforming the Dow recently — reinforcement for bullish sentiment and potential technical buying. Amgen stock hits all-time high Is Amgen Stock Outperforming the Dow?
• Neutral Sentiment: Biotech sector activity: a large biotech IPO (Generate Biomedicines) indicates healthy capital markets for life sciences, which can be a neutral tailwind for large biotech names but doesn’t directly change Amgen’s fundamentals. Generate caps a strong month for biotech IPOs
• Neutral Sentiment: Minor portfolio rebalancing: a small sale by Bradley Foster & Sargent reduced a modest position in AMGN — not material to shares outstanding or sentiment. Bradley Foster & Sargent sells AMGN
• Negative Sentiment: Policy risk: a proposed U.S. bill to tighten rules on corporate inversions mentions AMGN among companies potentially affected by changes to international tax treatment — could raise longer‑term tax/structural uncertainty if enacted. Impact is uncertain and likely small near term. Stop Corporate Inversions Act of 2026
• Neutral Sentiment: Reported short‑interest data in feeds looks inconsistent (zeros/NaN) and should be treated with caution; no clear signal from short interest trends. (data sources above).

Analyst Ratings Changes

A number of research firms have recently commented on AMGN. Freedom Capital cut shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. The Goldman Sachs Group lifted their target price on Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Scotiabank initiated coverage on Amgen in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price objective on the stock. Finally, BMO Capital Markets lifted their price objective on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $351.76.

Amgen Stock Up 2.3%

Amgen stock opened at $388.16 on Monday. Amgen Inc. has a one year low of $261.43 and a one year high of $390.14. The stock has a fifty day moving average of $348.89 and a 200 day moving average of $319.93. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The stock has a market cap of $209.25 billion, a PE ratio of 27.28, a price-to-earnings-growth ratio of 3.85 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same period last year, the firm posted $5.31 earnings per share. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a $2.52 dividend. The ex-dividend date is Friday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a yield of 2.6%. Amgen’s payout ratio is 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.